Multi-cancer early detection (MCED) testing is generating significant excitement—but what does the evidence actually support? In this data-driven session, Dr. Candace Westgate will review the current science behind MCED technologies, including test performance, clinical utility, and implementation challenges. Drawing on her experience integrating preventive tools into practice, she’ll explore where MCED testing fits into the future of cancer screening and how clinicians can approach its use with clarity and caution.

Candace Westgate, DO, MPH, FACOG, MSCP, is a board-certified OB/GYN with advanced training in minimally invasive gynecologic surgery, menopause management, and cancer genetics. She holds additional certifications in advanced laparoscopy, ACOG’s Women’s Genomics Counseling Course, and the City of Hope Intensive Course in Hereditary Cancer Risk Assessment. Dr. Westgate earned her Master of Public Health from Tulane University with a focus on program management and maternal and child health. She completed her medical education at Kirksville College of Osteopathic Medicine and her OB/GYN residency at Georgetown University Hospital in Washington, DC. A national leader in early detection and personalized medicine, Dr. Westgate previously served as Medical Director of the Adventist Health AHEAD Program and now leads Personalized Medicine at Community Health. She is passionate about equipping patients with innovative, genomics-informed tools to take charge of their health and detect cancer at its earliest—and most treatable—stages.